MedTrace Logo

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2019-11-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).

Conditions

  • Alzheimer Disease

Interventions

DRUG

Placebo Control

ELND005 matched placebo capsules for oral administration, bid for 78 weeks

DRUG

ELND005

ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks

DRUG

ELND005

ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks

DRUG

ELND005

ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks

Sponsors & Collaborators

  • OPKO Health, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568776 on ClinicalTrials.gov